Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery

Ann Surg Oncol. 2023 Feb;30(2):680-682. doi: 10.1245/s10434-022-12725-4. Epub 2022 Oct 28.

¹ Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² San Luigi Gonzaga Hospital, University of Turin, Turin, Italy.
³ Medical Oncology, Department of Medical and Surgical Specialities, Radiological Sciences and Public Health University of Brescia, ASSAT-Spedali Civili, Brescia, Italy.
⁴ Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. jonathan.hernandez@nih.gov.
⁵ Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, USA. mahabra@mdanderson.org.

No abstract available

Publication types